AbCellera Biologics Inc vs Nasdaq100 ETF — how do they compare? AbCellera Biologics Inc trades at $10.31 (market cap $2.99B), while Nasdaq100 ETF trades at $723.03. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Nasdaq100 ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | QQQ | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | — |
52-Week High | $9.76 | $746.16 |
52-Week Low | $2.78 | $558.34 |
Enterprise Value | $2.58B | — |
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
QQQ trades at $723.65, up 0.39% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. The ETF's momentum is supported by positive market breadth and tech earnings beats, though RSI levels suggest some near-term overbought conditions. A dividend of $0.81 per share is scheduled for July 2026.
Outlook remains positive given strong tech sector performance and institutional inflows, but risks include high valuation sensitivity and market volatility. Analyst sentiment is split evenly between buy and sell recommendations, reflecting uncertainty over sustained growth versus potential pullbacks.
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →